首頁
Recro Pharma, Inc.

7月 2026Recro Pharma, Inc.的市場佔有率分析

at societal™ cdmo is a contract development and manufacturing organization (cdmo) partner with locations on both coasts of the us.

健康 > 生物技術和製藥

域名recropharma.com

成立年份2007

僱員201 - 500

年度營收$75M - $100M

Recro Pharma, Inc.

Recro Pharma, Inc.（包含公司地區）

recropharma.com

查看更多網站流量與參與度資訊

Recro Pharma, Inc.截至 7月 2026 的總收入為 75M - 100M

Recro Pharma, Inc. 熱門網域產生的總收入

Recro Pharma, Inc. 熱門網域 3 年內的總收入

Recro Pharma, Inc. 熱門網域的總收入

recropharma.com75M - 100M

透過銷售情報查看更多內容

Recro Pharma, Inc.的熱門網域總造訪量

了解Recro Pharma, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

Recro Pharma, Inc.的熱門網域平均造訪時長

分析Recro Pharma, Inc.參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

Recro Pharma, Inc.的熱門網域平均頁面瀏覽量

了解Recro Pharma, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

Recro Pharma, Inc.按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

menariniapac.com公司名Menarini Asia-Pacific僱員1001 - 5000總部新加坡, Singapore年度營收> $1B訪問總量10.4K健康 > 生物技術和製藥

使用的熱門技術Recro Pharma, Inc.

这些是Recro Pharma, Inc.顶级域名使用的行业网站技术

付費廣告 (9)

DoubleClick

小工具 (4)

reCAPTCHA

轉換與分析 (2)

Google Analytics

行動裝置 (2)

Meta Viewport

更多技術

8

檢視所有

新聞與訊號來自Recro Pharma, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Recro Pharma, Inc. hired Eduardo Uribe as head of quality for Recro San Diego on Jan 19th '22.Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Eduardo Uribe as the company’s head of quality for Recro San Diego.

新聞Recro Pharma, Inc. hired Bourque as senior director of supply chain and facilities on Sep 6th '21.Mr. Bourque joined Recro from Ajinomoto Bio-Pharma Services, where he was most recently senior director of supply chain and facilities.

新聞Recro Pharma, Inc. signed new client National Center for Advancing Translational Sciences on Oct 20th '21.Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).